This single-center retrospective study evaluated azacitidine as maintenance therapy after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with high-risk acute myeloid leukemia (AML).
Single-center retrospective design limits generalizability and introduces selection bias; no randomized comparator arm; sample size and follow-up duration are not reported in the available metadata.
Azacitidine maintenance post-allo-HSCT may be considered in high-risk AML, but clinicians should interpret findings cautiously given the retrospective, single-center nature of this study and await prospective data.
Explore related topics